Phase II trial of palbociclib with fulvestrant in individuals with hormone receptorpositive, HER2-negative metastatic breast cancer with disease progression after palbociclib with an aromatase inhibitor
CANCER RESEARCH(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要